Related Experiment Video
Updated: Aug 21, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Updates on Pharmacologic Management of Microvascular Angina
Mosayeb Soleymani1, Farzad Masoudkabir2,3, Mahsima Shabani4
1Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Microvascular angina (MVA), a common cause of chest pain without blocked arteries, presents a treatment challenge. Beta-blockers and calcium channel blockers offer the most symptom relief for this condition.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Microvascular angina (MVA), also known as cardiac syndrome X, affects predominantly women with angina and nonobstructive coronary artery disease.
- MVA poses a significant healthcare burden due to repeated diagnostic procedures and hospitalizations.
- Current management strategies for MVA are limited, highlighting a gap in evidence-based guidelines.
Purpose of the Study:
- To review the underlying mechanisms of MVA.
- To summarize the outcomes of various pharmacologic interventions for MVA.
- To provide an updated overview of MVA treatment options.
Main Methods:
- Literature review of studies on MVA pathophysiology.
- Analysis of clinical trial data on medications used for MVA.
- Synthesis of current knowledge on pharmacologic management of MVA.
Main Results:
- Nitrates are ineffective for MVA, unlike vasospastic angina.
- Beta-blockers and calcium channel blockers demonstrate the strongest evidence for symptom improvement.
- ACE inhibitors, ARBs, statins, estrogen, and novel antianginal drugs show promising results.
- Emerging therapies like vitamin D, omega-3, incretins, and N-acetyl cysteine show initial benefits.
Conclusions:
- Effective management of MVA requires further research and guideline development.
- Integrating current and future trial results into cardiac care guidelines can reduce healthcare costs.
- Pharmacologic interventions, particularly beta-blockers and calcium channel blockers, are key to managing MVA symptoms.
Abstract:
Microvascular angina (MVA), historically called cardiac syndrome X, refers to angina with nonobstructive coronary artery disease. This female-predominant cardiovascular disorder adds considerable health-related costs due to repeated diagnostic angiography and frequent hospital admissions. Despite the high prevalence of this diagnosis in patients undergoing coronary angiography, it is still a therapeutic challenge for cardiologists. Unlike obstructive coronary artery disease, with multiple evidence-based therapies and management guidelines, little is known regarding the management of MVA. During the last decade, many therapeutic interventions have been suggested for the treatment of MVA. However, there is a lack of summarization tab and update of current knowledge about pharmacologic management of MVA, mostly due to unclear pathophysiology. In this article, we have reviewed the underlying mechanisms of MVA and the outcomes of various medications in patients with this disease. Contrary to vasospastic angina in which normal angiogram is observed as well, nitrates are not effective in the treatment of MVA. Beta-blockers and calcium channel blockers have the strongest evidence of improving the symptoms. Moreover, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, estrogen, and novel antianginal drugs has had promising outcomes. Investigations are still ongoing for vitamin D, omega-3, incretins, and n-acetyl cysteine, which have resulted in beneficial initial outcomes. We believe that the employment of the available results and results of the future large-scale trials into cardiac care guidelines would help reduce the global cost of cardiac care tremendously.
More Related Videos
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
Angina IV: Management
Angina V: Nursing Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care